Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunovantIMVT +0.36%29 Price-to-Tangible-Book is 11.01 as of Sep. 08, 2026. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Immunovant ranks worse than 84.03% on this metric.
As of today (2026-09-08), Immunovant's share price is $39.25. Immunovant's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $3.57. Hence, Immunovant's Price to Tangible Book Ratio of today is 11.01.
The historical rank and industry rank for Immunovant's Price-to-Tangible-Book or its related term are showing as below:
IMVT'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.04 Med: 5.58 Max: 20.04
Current: 10.99
During the past 8 years, Immunovant's highest Price to Tangible Book Ratio was 20.04. The lowest was 1.04. And the median was 5.58.
IMVT's Price-to-Tangible-Book is ranked worse than 84.03% of 1127
companies
in the Biotechnology industry
Industry Median: 3.38
vs IMVT: 10.99
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Immunovant Price-to-Tangible-Book Related Terms
Immunovant Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Immunovant's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMVT vs IBRX, TGTX, PCVX: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Immunovant's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovant Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunovant's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Immunovant's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Immunovant (IMVT) has a Price-to-Tangible-Book of 11.01 as of Sep. 08, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Immunovant and its competitors. According to the industry distribution chart, Immunovant ranks #947 out of 1127 companies in the Biotechnology industry, placing it in the top 84%.
Is Immunovant's Price-to-Tangible-Book too high?
Immunovant's current Price-to-Tangible-Book is 11.01. The Biotechnology industry median Price-to-Tangible-Book is 3.38. Immunovant's value of 11.01 is 225.7% above this industry median. Based on the distribution chart, Immunovant ranks #947 out of 1127 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's Price-to-Tangible-Book compare to IBRX and TGTX?
According to the Biotechnology industry distribution chart, Immunovant ranks #947 out of 1127 companies for Price-to-Tangible-Book. This places Immunovant in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.38. Immunovant's value of 11.01 is 225.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.38, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunovant's current Price-to-Tangible-Book of 11.01 is 225.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Immunovant and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovant's current Price-to-Tangible-Book is 11.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current Price-to-Tangible-Book of 11.01. The current Price-to-Tangible-Book is 11.01 and 225.7% above the Biotechnology industry median of 3.38. Immunovant's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Immunovant (IMVT), the current Price-to-Tangible-Book is 11.01 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score
Get the complete analysis for IMVT
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMVT has been successfully added to your 
